Net sales and EBIT were slightly below market consensus (LSEG) in Q2.
Redeye remains confident on the case and leave our forecasts and valuation virtually unchanged follo...
Redeye comments on Vertiseit’s Q2 report, showing solid underlying ARR growth and an adjusted EBITDA...
Redeye updates its estimates and valuation for Serstech following the Q2 2025 report.
Selective recruitment in H2'25 Q2 missed on sales and adj.
Solid order bookings given a cautious market The Q2 report showed lower sales than we expected, as w...
Redeye provides an initial comment on the Q2 2025 report from Serstech.
Redeye comments on the conversion of warrants and Cantargia's deal yesterday.
Finnair’s Q2 revenue fell a bit short of estimates as ticket prices developed slightly softer than e...
Oriola More cautious stance on Wholesale profitability Oriola reports its Q2 results on July 18th.
Adjusted for currency effects, Enea’s net sales of SEK234.
Redeye returns with a more in-depth take on the Q2 report.
Redeye comments on CMS’s preliminary CPT-I codes payment rates.
Redeye updates its estimates and valuation after Indutrade’s Q2 2025 report.
Redeye comments on Cantargia’s license deal with Otsaka Pharmaceutical, which is transformative for ...
Redeye keeps its Base Case unchanged and makes minor estimate revisions following a Q2 report roughl...
Redeye gives its initial take on BONESUPPORT’s Q2 report.
Consti’s Q2/2025 figures are due on Friday, July 18.
Better Norway offset by losses in Denmark Coor managed to turn both organic sales and EBITA growth p...
Q2 expectations Prevas will release its Q2'25 report on 17 July, and we expect SEK 428m in sales, im...
